Filtered By:
Drug: Colchicine
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 88 results found since Jan 2013.
Effect of different doses of colchicine on high sensitivity C-reactive protein in patients with acute minor stroke or transient ischemic attack: A pilot randomized controlled trial
CONCLUSION: Early treatment with low dose of colchicine reduced hsCRP levels in the patients with acute minor ischemic stroke and TIA.PMID:36041708 | DOI:10.1016/j.ejps.2022.106288
Source: European Journal of Pharmaceutical Sciences - August 30, 2022 Category: Drugs & Pharmacology Authors: Baoshi Yuan Xia Meng Anxin Wang Siying Niu Xuewei Xie Jing Jing Hao Li Liguo Chang Yongjun Wang Jiejie Li Source Type: research
Colchicine may become a new cornerstone therapy for coronary artery disease: a meta ‐analysis of randomized controlled trials
AbstractPurposeColchicine is an ancient anti-inflammatory drug. In recent years, an increasing number of studies have shown that colchicine improves the prognosis of patients with coronary artery disease (CAD), while other studies have reported the opposite. The aim of this study was to evaluate the relative efficacy and safety of colchicine in treating CAD.MethodsPubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov were searched from inception to 20 October 2020 for randomized controlled trials (RCTs) comparing colchicine and placebo in patients with CAD. The primary outcomes were the primary composite outcomes of...
Source: Clinical Rheumatology - February 9, 2022 Category: Rheumatology Source Type: research
Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Conclusion and Perspectives
Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions.
Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research
Inflammation May Be the Culprit Behind Our Deadliest Diseases
In the early days of my medical residency, I met a man whom we’ll call Jason. He arrived to our emergency room on a holiday, nonchalant yet amiable, and complained of mild chest pain. Jason was tall and trim, with a strong South Boston accent and fingertips still faintly stained from his last home-improvement project. He was only 45 years old, but he looked much younger. He didn’t smoke, barely drank alcohol, and his cholesterol levels had always been normal. No one in his family had a history of heart disease. He asked us if we could work quickly—he wanted to be home for dinner with his daughters.
[time-...
Source: TIME: Health - April 11, 2023 Category: Consumer Health News Authors: Shilpa Ravella Tags: Uncategorized freelance health Source Type: news
Management of postoperative atrial fibrillation after cardiac surgery
This article will review the available evidence on the prevention and treatment of atrial fibrillation after cardiac surgery. Using this knowledge, we propose a conceptual framework on the management of patients with POAF during various phases after cardiac surgery.
Recent findings: Perioperative β-blockade is the cornerstone in preventing POAF after cardiac surgery. Results from randomized trials do not support routine use of colchicine or corticosteroids to prevent POAF. There is no study examining the impact of rate versus rhythm control on ‘hard’ clinical outcomes such as mortality or stroke in the cardiac surgic...
Source: Current Opinion in Cardiology - February 5, 2016 Category: Cardiology Tags: VALVULAR HEART DISEASE: Edited by Subodh Verma Source Type: research
The Role of Colchicine in the Prevention of Cerebrovascular Ischemia.
CONCLUSION: Inflammatory pathways seem to be key mediators in the development of atherosclerotic process, atheromatous plaque destabilization and thromboembolism. Colchicine as a novel therapeutic agent could be a safe and effective inhibitor of the inflammation cascade in patients with extra- or intracranial atherosclerosis or arteriolosclerosis, resulting in reduced vascular events.
PMID: 29336246 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - January 15, 2018 Category: Drugs & Pharmacology Authors: Tsivgoulis G, Katsanos AH, Giannopoulos G, Panagopoulou V, Jatuzis D, Lemnens R, Deftereos S, Kelly PJ Tags: Curr Pharm Des Source Type: research
Safety and Efficacy of Colchicine in Patients with Stable CAD and ACS: A Systematic Review and Meta-analysis
ConclusionIn patients presenting with ACS, low-dose colchicine might reduce the incidence of MACE, stroke, and the need for revascularization at long follow-up durations. Colchicine might offer no benefits in reducing the risk of ischemic events in patients with stable angina.
Source: American Journal of Cardiovascular Drugs - June 21, 2021 Category: Cardiology Source Type: research
Is Intracranial Arterial Involvement A Subgroup of Neuro-Behcet Syndrome? (P5.035)
Conclusion:Neurological involvement in BS patients is generally due to venous inflammation. Intracranial arterial involvement in NBS is rare, but it should be kept in mind that it can occur during the course of the disease independent of other stroke risk factors.Disclosure: Dr. Zeydan has nothing to disclose. Dr. Uygunoglu has received personal compensation for activities with Merck Serono, Biogen Idec, Novartis and Allergan Inc. as an attendee at congresses or symposia. Dr. Tutuncu has nothing to disclose. Dr. Yalcinkaya has nothing to disclose. Dr. Altintas has received personal compensation for activities with The Scie...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Zeydan, B., Uygunoglu, U., Tutuncu, M., Yalcinkaya, C., Altintas, A., Saipoglu, S., Siva, A. Tags: General Neurology IV Source Type: research
Neuroprotective Mechanisms Mediated by CDK5 Inhibition.
This article discusses current evidence for the involvement of CDK5 deregulation in neurodegenerative disorders and neurodegeneration associated with stroke through various mechanisms. These include upregulation of cyclin D1 and overactivation of CDK5 mediated neuronal cell death pathways, aberrant hyperphosphorylation of human tau proteins and/or neurofilament proteins, formation of neurofibrillary lesions, excitotoxicity, cytoskeletal disruption, motor neuron death (due to abnormally high levels of CDK5/p25) and colchicine-induced apoptosis in cerebellar granule neurons. A better understanding of the role of CDK5 inhibit...
Source: Current Pharmaceutical Design - November 24, 2015 Category: Drugs & Pharmacology Authors: Mushtaq G, Greig NH, Anwar F, Al-Abbasi FA, Zamzami MA, Al-Talhi HA, Kamal MA Tags: Curr Pharm Des Source Type: research
Colchicine for prevention of cardiovascular events.
CONCLUSIONS: There is much uncertainty surrounding the benefits and harms of colchicine treatment. Colchicine may have substantial benefits in reducing myocardial infarction in selected high-risk populations but uncertainty about the size of the effect on survival and other cardiovascular outcomes is high, especially in the general population from which most of the studies in our review were drawn. Colchicine is associated with gastrointestinal side effects based on low-quality evidence. More evidence from large-scale randomised trials is needed.
PMID: 26816301 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - January 27, 2016 Category: Journals (General) Authors: Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M, Glinz D, Nordmann AJ, Briel M Tags: Cochrane Database Syst Rev Source Type: research
Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions
AbstractPurpose of the ReviewThis review highlights selected cardiovascular disease (CVD) prevention studies presented at the 2019 American Heart Association (AHA) Scientific Sessions.Recent FindingsSeveral important cardiovascular prevention studies were presented at the 2019 AHA Scientific Sessions. Results from the Colchicine Cardiovascular Outcomes Trial (COLCOT) showed that low-dose colchicine reduces the risk of recurrent CVD events among patients with recent myocardial infarction. A prospective analysis from the UK Biobank cohort demonstrated that the increased CVD risk associated with clonal hematopoiesis of indete...
Source: Current Atherosclerosis Reports - January 10, 2020 Category: Cardiology Source Type: research
